Log in to your Inderes Free account to see all free content on this page.
Create account

Cinclus Pharma

12.24 SEK

-1.29 %

Less than 1K followers

CINPHA

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

-1.29 %
-31.62 %
-34.75 %
-36.45 %
-23.40 %
+12.29 %
-
-
-62.46 %

Cinclus Pharma is a Swedish clinical-stage pharmaceutical company. The company is active in the development of molecules for the treatment of acid-related diseases. The company's lead drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and is headquartered in Stockholm, Sweden.

Read more
Market cap
580.08M SEK
Turnover
5.75M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
13.5.
2026

Interim report Q1'26

21.5.
2026

General meeting '26

19.8.
2026

Interim report Q2'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.